

REMARKS

The foregoing amendments are effected to more particularly point out and distinctly define the subject matter of this invention.

Enclosed herewith is a revised Sequence Listing in both a paper and computer readable form (CRF). The content of the paper and CRF are the same. The revised Listing recites the amino acid sequences in three letter code as opposed to the one letter code as in the original Sequence Listing. No new matter has been added.

The specification is amended to include a Brief Description for Fig. 15. Support can be found in Fig. 15 and the description in Example 9 on page 23.

The specification at page 6, line 18 and at page 18, line 21 is amended to recite the correct measurement as supported by the disclosure at page 18, line 15.

The specification at page 11, lines 17-18 is amended to delete “and C181 variant cNOS of N-Ras.”

The specification at page 17, line 1 is amended to delete “(CGY).”


Claims 1 and 2 are amended to replace “a polypeptide specifically bound to the lipid second messenger” with “a polypeptide which can specifically bind the lipid second messenger.” Support can be found in original claims 1 and 2 and Fig. 1A. The amended claim terminology is a correct translation from the original Japanese text.

Therefore, no new matter has been added by this amendment.

Favorable action on the merits is solicited.

Respectfully submitted,

Yoshio UMEZAWA et al.

By: 
Jay F. Williams
Registration No. 48,036
for
Warren M. Cheek, Jr.
Registration No. 33,367
Attorneys for Applicants

WMC/JFW/akl
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
January 20, 2006